uniQure (NASDAQ:QURE) Shares Gap Down – Should You Sell?

uniQure (NASDAQ:QURE) shares gapped down prior to trading on Tuesday . The stock had previously closed at $14.53, but opened at $14.07. uniQure shares last traded at $13.83, with a volume of 60,923 shares.

Wall Street Analyst Weigh In

Several brokerages have commented on QURE. Leerink Partners upped their price target on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. Guggenheim reissued a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price target on shares of uniQure in a research report on Tuesday, January 21st. Stifel Nicolaus lifted their price target on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. Finally, Wells Fargo & Company reduced their price objective on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $38.89.

uniQure Stock Down 0.3 %

The firm has a 50-day moving average of $13.95 and a two-hundred day moving average of $10.31. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $783.25 million, a price-to-earnings ratio of -2.92 and a beta of 0.36.

Insider Transactions at uniQure

In other news, CFO Christian Klemt sold 14,341 shares of the business’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70. Following the transaction, the chief financial officer now owns 152,372 shares in the company, valued at approximately $1,630,380.40. The trade was a 8.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Matthew C. Kapusta sold 6,717 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $76,036.44. Following the completion of the sale, the chief executive officer now owns 580,795 shares of the company’s stock, valued at approximately $6,574,599.40. The trade was a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 90,830 shares of company stock valued at $961,401 in the last three months. Corporate insiders own 4.74% of the company’s stock.

Institutional Trading of uniQure

Several institutional investors have recently modified their holdings of the company. Atria Investments Inc acquired a new stake in shares of uniQure in the third quarter valued at approximately $53,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of uniQure during the third quarter valued at $69,000. Charles Schwab Investment Management Inc. increased its position in uniQure by 6.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 277,275 shares of the biotechnology company’s stock worth $1,367,000 after purchasing an additional 16,464 shares during the period. FMR LLC raised its holdings in uniQure by 8,056.6% during the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after purchasing an additional 346,274 shares during the last quarter. Finally, PEAK6 Investments LLC acquired a new position in uniQure during the 3rd quarter valued at about $260,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.